Medical Cannabis Formulations
Chronic Pain
Key Facts
About Aurora Cannabis
Aurora Cannabis is a vertically integrated cannabis company with a dual mission: to be a leading supplier in the global adult-use market and to advance the science of medical cannabis through clinical research and product standardization. The company achieved rapid scale post-Canadian legalization, constructing some of the world's largest automated cultivation facilities and establishing a significant international medical export footprint. Its current strategy focuses on achieving positive free cash flow by rationalizing operations, optimizing its asset base, and targeting high-margin medical segments domestically and abroad, particularly in Europe and Australia.
View full company profileAbout Aurora Cannabis
Aurora Cannabis is a vertically integrated cannabis company with a dual mission: to be a leading supplier in the global adult-use market and to advance the science of medical cannabis through clinical research and product standardization. The company achieved rapid scale post-Canadian legalization, constructing some of the world's largest automated cultivation facilities and establishing a significant international medical export footprint. Its current strategy focuses on achieving positive free cash flow by rationalizing operations, optimizing its asset base, and targeting high-margin medical segments domestically and abroad, particularly in Europe and Australia.
View full company profileAbout Aurora Cannabis
Aurora Cannabis is a vertically integrated cannabis company with a dual mission: to be a leading supplier in the global adult-use market and to advance the science of medical cannabis through clinical research and product standardization. The company achieved rapid scale post-Canadian legalization, constructing some of the world's largest automated cultivation facilities and establishing a significant international medical export footprint. Its current strategy focuses on achieving positive free cash flow by rationalizing operations, optimizing its asset base, and targeting high-margin medical segments domestically and abroad, particularly in Europe and Australia.
View full company profileTherapeutic Areas
Other Chronic Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| SCI-160 | SciSparc | Preclinical |
| Injectrode Platform for Chronic Pain | Neuronoff | Pre-clinical |
| Novel PNS System | Nervonik | First-in-Human Completed |
| Pain Pipeline | Centrexion Therapeutics | Clinical Stage |
| High-Definition Spinal Cord Stimulation | Micro-Leads | Unknown |
| Precision Medicine for Pain | MindX Sciences | Commercial |
| Chronic Pain Program | Current Surgical | Research |
| N-19a | Neurocarrus | Pre-clinical |
| Nav1.7 ASO | Quiver Bioscience | Discovery |
| Nav1.8 ASO | Quiver Bioscience | Discovery |
| Dual Nav1.7/1.8 ASO | Quiver Bioscience | Discovery |
| TMS for Chronic Pain | Magstim | Commercial/Clinical Development |